TargaZyme

Lynnet Koh has extensive Senior and C-level executive experience in biotech, wireless, internet, consumer products’ industries with expertise in leading major new technology/product innovation, new product design, development and commercialization of cutting-edge technologies and products that became standards with multi-billion-dollar revenues. Ms. Koh has also led numerous financial transactions including raising over $200m for her various development-stage enterprises and completed nearly $600m in M&A (all cash deals) and licensing transactions.

Experienced proven professional in marketing and real estate operations including day to day management and leasing/sales. Proven background in renovations and positioning of real estate to maximize value. Track record includes multi-family, office, retail, industrial and specialty properties.

Dr. Jakubowski is a highly experienced Regulatory Affairs executive with over 35 years managing the regulation of medicines and experience at large and small companies alike. Dr. Jakubowski is particularly familiar with the regulatory requirements related to novel medicines and high, unmet medical needs which explains her attraction to and interest in working with TargaZyme.

PhD oncology drug discovery scientist and senior manager with more than 25 years experience in research and development, from discovery to registration, and with extensive experience in oncology, inflammation, apoptosis, nuclear receptor biology, hematology and cytokine biology Specialties: - Oncology, Immunology (immuno-oncology), small molecule, protein/peptide, biologics, adoptive cell therapies, drug development - Strong hands-on laboratory experience assay development (yeah, I remember being a lab rat) - Translational research, mechanism of action, biomarker identification and validation, non clinical IND enabling. - Regulatory agency submissions (IND, NDA, Investigator’s Brochure) - Strong communication and presentation skills - Multidisciplinary team environment. - Managing PhD and non-PhD scientists, external academic collaborations and contract research organizations.

Experienced pharmaceutical executive with over 20 years of drug discovery and development experience. An excellent track record of bringing hits to leads and optimizing compounds into development candidates. Energetic leader with a proven track record to attract, lead, mentor and motivate a strong group of chemists. Directed many successful programs of which 4 compounds are currently in the clinic. Managed manufacturing, CMC and supply chain for Apricus'​ internal pipeline including clinical and commercial products. Involved in CMC and regulatory work for the approval of Apricus Biosciences' (NexMed) first drug Vitaros in Canada and Europe. Acting vice president of CMC and Head of Operations at Targazyme. Currently leading technical operations at Travere Therapeutics. Specialties: Medicinal, automation and analytical chemistry. Manufacturing, CMC and Supply Chain. Intellectual property and patent filings. Drug Discovery and development in the fields of inflammation, oncology, virology, cardiovascular and metabolic diseases. Project/Program management and collaboration with big Pharma Directing CROs and CMOs Formulation and DMPK

Developing the first class personalized immunotherapy, Antibody-Drug Conjugate therapy (HER2+, HER3+, triple negative metastatic breast cancer and other tumors) and oncolytic virus therapy for cancer. Leader in drug development, and executive leadership skills of pharmaceuticals. Leader in medical research, clinical development, clinical operations and medical affairs of cancer drug and commercialization. Trained at Walter Reed Army Institute of Research and Walter Reed Army Medical Center, Washington, DC, USA, NCI, Bethesda, MD, & School of Medicine Nagasaki University, Japan. Leader in Oncology phase 1-4 drug development; first-in-human, and full development of solid tumors, leukemias and lymphomas; immuno-oncology, cell therapy, oncolytic virus therapy, chemotherapy and commercialization. Experienced Executive working in start-up and large pharma, INDs and NDAs submissions to US FDA, EU and Japan. • Expert in global drug safety, pharmacovigilance of pre- and post-marketed products. • Experience in viral RNA vaccine clinical trials and safety monitoring • Experienced in regulatory; FDA, EMA, DCGI, MHLW, support FDA CRLs questions

Experienced Chairman with a demonstrated history of working in the biotechnology industry. Skilled in Translational Research, Biomarkers, Protein Chemistry, Medical Devices, and Vaccines. Strong entrepreneurship professional graduated from Yale University School of Medicine.